US36254L3087 - Common Stock
GT BIOPHARMA INC
NASDAQ:GTBP (12/23/2024, 8:09:24 PM)
After market: 2.7 -0.11 (-3.91%)2.81
+1.07 (+61.03%)
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The company is headquartered in San Francisco, California and currently employs 2 full-time employees. The company went IPO on 2013-10-22. The firm is focused on the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. Its TriKE platform generates therapeutics designed to harness and enhance the cancer killing abilities of a patient’s own natural killer (NK) cells. The firm is also using its TriKE platform to develop therapeutics useful for the treatment of infectious disease such as for the treatment of patients infected by the human immunodeficiency virus (HIV). Its GTB-3550 is the first-generation TriKE product candidate which was a single-chain, tri-specific recombinant fusion protein construct composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15, all connected by small peptide linkers.
GT BIOPHARMA INC
315 Montgomery Street, 10Th Floor
San Francisco CALIFORNIA 90212
P: 18003049888
CEO: Anthony J. Cataldo
Employees: 2
Website: https://www.gtbiopharma.com/
GTB-3650 TriKE® Phase 1 trial first patient dosed expected in Q4 2024; initial clinical data expected in Q2 2025GTB-5550 TriKE® IND submission for...
SAN FRANCISCO, CALIFORNIA, Sept. 26, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company...
SAN FRANCISCO, CALIFORNIA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company...
GT Biopharma just reported results for the second quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips GT Biopharma (NASDAQ:GTBP) just reported results for the second quarter of 2024...
GTB-3650 TriKE® Phase 1 trial initiation expected in 2H 2024; initial clinical data expected in 1H 2025GTB-5550 TriKE® IND submission for treatment of B7H3...
Here you can normally see the latest stock twits on GTBP, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: